Last reviewed · How we verify
Clostridium difficile infection — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Zinplava | BEZLOTOXUMAB | Merck & Co. | 2016-01-01 | |||
| Dificid | FIDAXOMICIN | Cubist Pharms Llc | Macrolide Antibacterial [EPC] | 2011-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Cubist Pharms Llc · 1 drug in Clostridium difficile infection
- Merck & Co. · 1 drug in Clostridium difficile infection
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Clostridium difficile infection:
- Clostridium difficile infection treatment updates — RSS
- Clostridium difficile infection treatment updates — Atom
- Clostridium difficile infection treatment updates — JSON
Cite this brief
Drug Landscape (2026). Clostridium difficile infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/clostridium-difficile-infection. Accessed 2026-06-10.
Related
- Clostridium difficile infection full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing